The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
CR888
Not strictly true, I have also contacted investors relations and had the following reply
ā Hi Jason,
Thanks for your interest in Darktrace.
You are right, we announced the independent third part review in February, and we said it would take months not weeks to complete. We are allowing EY to drive the timeline, they need to do their work thoroughly, and we are happy for them to take the time they need. When they complete their work, they will report to Paul Harrison (head of audit and risk committee) and then it will be made public to our external stakeholders.
Timing is not in our control, so I cannot comment, but we look forward to publishing in due course.
As always, our next trading update (for the June quarter) will be in July.
If you wish to be added to our investor relations email list (where we share key announcements, like product updates and senior hires ā e.g. our recent CMO hire last week) then let us know and we can add your email address to that list. In due course when we publish EY conclusion, we would also email that distribution listā
WTF!